FDA approves donanemab, Eli Lilly’s treatment for early Alzheimer’s disease
Donanemab, made by Indianapolis-based Eli Lilly, works by helping the body remove amyloid plaque buildup in the brain, a hallmark of Alzheimer’s disease.
Get CNN Health's weekly newsletter
- Sign up here to get The Results Are In with Dr. Sanjay Gupta every Tuesday from the CNN Health team.
Lilly said it will be sold under the name Kisunla and would cost $695 per vial before insurance, what would amount to $12,522 for a six-month course or about $32,000 for a year.
This is a developing story and will be updated.
The development of Donanemab by Eli Lilly could potentially improve overall health by alleviating symptoms related to Alzheimer's disease. Despite its high cost, accessing this treatment through insurance could still be a viable option for many patients seeking improved health outcomes.
